DNA-based GNOS-PV01 and peptide-based NeoVax show promise as personalized vaccines for glioblastoma, with GNOS-PV01 effective against the challenging MGMT-unmethylated subtype.
- In the news
Moving in Cancer Discovery.
Rebuilt
DNA-based GNOS-PV01 and peptide-based NeoVax show promise as personalized vaccines for glioblastoma, with GNOS-PV01 effective against the challenging MGMT-unmethylated subtype.
Newest first · last 60 days
NFIs act as conserved global temporal regulators of radial glial progenitor development, with mutations causing bidirectional impairments linked to human neocortical malformations.
Inhibiting autophagy with ATG7 silencing nanoparticles enhances radiotherapy effectiveness in high-grade mutant IDH1 gliomas, leading to tumor regression and long-term survival.
Levetiracetam extends survival in children with diffuse midline glioma by targeting GABAergic synapses, but not in other glioma subtypes.
Spatial organization of IDH-mutant gliomas shifts from anatomy-driven in low-grade tumors to hypoxia-driven in high-grade tumors, revealing two distinct axes of tumor structure.
Mapping 202 MRI-localized biopsies from 58 glioma patients reveals three key tissue states and 14 MRI habitats linked to tumor biology and progression.
Eighteen candidate TCDD-associated targets, including five hub genes, were identified in retinoblastoma, with CDK1 showing the strongest link to cell-cycle dysregulation.
Endogenous immune responses, especially natural killer cell expansion, are crucial for successful CAR T cell therapy in recurrent GBM, with responders showing significant immune remodeling.
Journals this month
Moving areas, week to 3 Oct 2026